67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) Conference

Scholarly Activity

related documents

A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study Conferences